SCHEMBL3011745

SCHEMBL3011745

O=S(=O)(c1cc(Cl)ccc1Cl)C1CCN(c2nc(Cc3cccc(Br)c3)cs2)CC1

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
RECQL P46063 1/20 0.35
CTSS P25774 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TSHR P16473 3/20 0.34
HTT P42858 2/20 0.34
MAPK1 P28482 1/20 0.34
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.33
ALOX15 P16050 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
POLB P06746 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
CNR1 P21554 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007871 0.93 CTSS (0.37) RAB9ASMN1; SMN2CTSSTSHRGAA
SCHEMBL3012034 0.91 CTSS (0.43) RAB9ASMN1; SMN2CTSSKMT2AMEN1
SCHEMBL3022234 0.91 RECQL (0.39) RAB9ASMN1; SMN2RECQLCTSSALDH1A1
SCHEMBL3018865 0.90 ALDH1A1 (0.39) RAB9ASMN1; SMN2RECQLCTSSALDH1A1
SCHEMBL3013907 0.89 CTSS (0.38) RAB9ASMN1; SMN2CTSSKMT2AMEN1
SCHEMBL3015793 0.89 ALDH1A1 (0.42) SMN1; SMN2RECQLALDH1A1TSHRMAPT
SCHEMBL3014353 0.89 KMT2A (0.38) RAB9ASMN1; SMN2CTSSALDH1A1TSHR
SCHEMBL3017119 0.89 DRD2 (0.39) RAB9ASMN1; SMN2ALDH1A1HTTMAPK1
SCHEMBL3011255 0.89 MAPT (0.37) RAB9ASMN1; SMN2RECQLALDH1A1TSHR
SCHEMBL3012479 0.89 MAPT (0.39) RAB9ASMN1; SMN2RECQLALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885SMN1; SMN2 1/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.